RALTEGRAVIR
New molecular entities (NMEs), as defined by the FDA, are new drug products containing, as their active ingredient, a chemical substance marketed for the first time in the United States.
Approximately 39.5 million people worldwide are infected with human immunodeficiency virus (HIV).